These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 25297751

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH.
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [Abstract] [Full Text] [Related]

  • 3. Epigenetic therapies move into new territory, but how exactly do they work?
    Tuma RS.
    J Natl Cancer Inst; 2009 Oct 07; 101(19):1300-1. PubMed ID: 19755677
    [No Abstract] [Full Text] [Related]

  • 4. DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?
    Ørskov AD, Grønbæk K.
    Cancer J; 2017 Oct 07; 23(5):277-285. PubMed ID: 28926428
    [Abstract] [Full Text] [Related]

  • 5. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
    Lowder JN, Taverna P, Issa JP.
    Epigenomics; 2015 Oct 07; 7(7):1083-8. PubMed ID: 26541345
    [No Abstract] [Full Text] [Related]

  • 6. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
    Daskalakis M, Blagitko-Dorfs N, Hackanson B, Lübbert M.
    Pharm Unserer Zeit; 2010 May 07; 39(3):217-27. PubMed ID: 20425776
    [No Abstract] [Full Text] [Related]

  • 7. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
    Lübbert M.
    Curr Top Microbiol Immunol; 2000 May 07; 249():135-64. PubMed ID: 10802943
    [No Abstract] [Full Text] [Related]

  • 8. [Treatment of MDS].
    Usuki K.
    Rinsho Ketsueki; 2014 Oct 07; 55(10):1882-92. PubMed ID: 25297752
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Demethylating medication in myelodysplastic syndrome].
    Manson ML, Derissen EJ, Wijermans PW, Schellens JH, Beijnen JH.
    Ned Tijdschr Geneeskd; 2012 Oct 07; 156(4):A3167. PubMed ID: 22278034
    [Abstract] [Full Text] [Related]

  • 11. Update on the pharmacotherapy for myelodysplastic syndromes.
    Duong VH, Komrokji RS, List AF.
    Expert Opin Pharmacother; 2014 Sep 07; 15(13):1811-25. PubMed ID: 25080144
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes.
    Carella AM.
    Eur J Haematol; 2015 Jun 07; 94(6):463. PubMed ID: 25702976
    [No Abstract] [Full Text] [Related]

  • 14. Azacitidine.
    Issa JP, Kantarjian HM, Kirkpatrick P.
    Nat Rev Drug Discov; 2005 Apr 07; 4(4):275-6. PubMed ID: 15861567
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Inoue A, Kawakami C, Takitani K, Tamai H.
    J Pediatr Hematol Oncol; 2014 Jul 07; 36(5):e322-4. PubMed ID: 24608072
    [Abstract] [Full Text] [Related]

  • 17. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
    Qin Y, Kuang P, Zeng Q, Wu Y, Liu T.
    Ann Hematol; 2019 Nov 07; 98(11):2523-2531. PubMed ID: 31637485
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.